Emerging dermatological and systemic applications of ustekinumab: beyond its clinical use in psoriasis.
作者信息
Kapoor Shailendra
机构信息
Richmond, VA, USA.
出版信息
Clin Cosmet Investig Dermatol. 2012;5:59-60. doi: 10.2147/CCID.S32149. Epub 2012 Jun 21.
Abstract
摘要
相似文献
1
Emerging dermatological and systemic applications of ustekinumab: beyond its clinical use in psoriasis.优特克单抗在皮肤科及全身性疾病中的新应用：超越其在银屑病中的临床应用。
Clin Cosmet Investig Dermatol. 2012;5:59-60. doi: 10.2147/CCID.S32149. Epub 2012 Jun 21.
2
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.英夫利昔单抗治疗伴有银屑病或银屑病关节炎的炎症性肠病患者的真实疗效：IG-IBD 研究。
Dig Liver Dis. 2019 Jul;51(7):972-977. doi: 10.1016/j.dld.2019.03.007. Epub 2019 Apr 13.
3
Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.在西班牙一个银屑病和银屑病关节炎患者队列的日常临床实践中使用优特克单抗进行治疗。
Clin Rheumatol. 2017 Feb;36(2):439-443. doi: 10.1007/s10067-016-3464-x. Epub 2016 Nov 5.
4
Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.优特克单抗：新药。怀疑有致癌性：对银屑病患者风险过大。
Prescrire Int. 2009 Oct;18(103):202-4.
5
Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.优特克单抗与其他全身治疗联合使用：在三级转诊中心的一项回顾性研究
J Drugs Dermatol. 2013 Oct;12(10):1098-102.
6
Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.乌司奴单抗与 TNF 抑制剂治疗银屑病或银屑病关节炎患者的心房颤动和心血管事件风险的相关性。
JAMA Dermatol. 2019 Jun 1;155(6):700-707. doi: 10.1001/jamadermatol.2019.0001.
7
Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.无论先前是否接受过生物制剂和非生物制剂的系统治疗，司库奇尤单抗治疗 12 周对中重度银屑病均持续有效：六项随机试验的事后分析。
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):928-937. doi: 10.1111/jdv.16982. Epub 2021 Feb 9.
8
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.中重度银屑病患者乌司奴单抗的长期安全性（第二部分）：来自 II 期和 III 期临床试验合并分析的感染和恶性肿瘤结果。
J Am Acad Dermatol. 2012 May;66(5):742-51. doi: 10.1016/j.jaad.2011.06.041. Epub 2011 Oct 5.
9
Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.乌司奴单抗在银屑病免疫病理学中的作用，重点关注Th17-IL23轴：入门指南。
J Biomed Biotechnol. 2012;2012:147413. doi: 10.1155/2012/147413. Epub 2012 Jun 12.
10
Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using F-fluorodeoxyglucose PET/CT.乌司奴单抗治疗与中重度银屑病患者全身和血管炎症减轻相关：使用 F-氟脱氧葡萄糖 PET/CT 的可行性研究。
J Am Acad Dermatol. 2019 May;80(5):1322-1331. doi: 10.1016/j.jaad.2018.03.011. Epub 2018 Mar 17.
本文引用的文献
1
Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.生物制剂治疗红皮病型银屑病的疗效和安全性：一项多中心、回顾性研究。
Br J Dermatol. 2012 Aug;167(2):417-23. doi: 10.1111/j.1365-2133.2012.10940.x. Epub 2012 Jun 11.
2
[Use of ustekinumab in inflammatory bowel disease: apropos of three cases].[乌司奴单抗在炎症性肠病中的应用：附三例报告]
Gastroenterol Hepatol. 2012 Jun-Jul;35(6):451-2. doi: 10.1016/j.gastrohep.2011.12.001. Epub 2012 Feb 7.
3
The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.两例患者在接受乌司奴单抗治疗银屑病后，迅速出现多发性鳞状细胞癌。
Australas J Dermatol. 2012 Feb;53(1):57-60. doi: 10.1111/j.1440-0960.2011.00853.x. Epub 2012 Jan 6.
4
Management of recalcitrant hidradenitis suppurativa with ustekinumab.用优特克单抗治疗顽固性化脓性汗腺炎
Acta Derm Venereol. 2012 May;92(3):320-1. doi: 10.2340/00015555-1229.
5
Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.难治性肿瘤坏死因子抑制剂诱导的掌跖脓疱病的治疗：2例报告
Arch Dermatol. 2011 Oct;147(10):1228-30. doi: 10.1001/archdermatol.2011.275.
6
Malignant melanoma during ustekinumab therapy of Crohn's disease.克罗恩病患者接受优特克单抗治疗期间发生恶性黑色素瘤。
Inflamm Bowel Dis. 2012 Jan;18(1):E199-200. doi: 10.1002/ibd.21877. Epub 2011 Oct 10.
7
Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD.优特克单抗在糖皮质激素难治性急性移植物抗宿主病中显示出活性。
Bone Marrow Transplant. 2012 May;47(5):747-8. doi: 10.1038/bmt.2011.172. Epub 2011 Aug 29.
8
Successful treatment of subacute lupus erythematosus with ustekinumab.使用优特克单抗成功治疗亚急性红斑狼疮。
Arch Dermatol. 2011 Aug;147(8):896-8. doi: 10.1001/archdermatol.2011.185.
9
Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.乌司奴单抗治疗甲银屑病：一项开放性、非对照、非随机研究。
J Dermatolog Treat. 2013 Apr;24(2):96-100. doi: 10.3109/09546634.2011.607796. Epub 2011 Aug 8.
10
Ustekinumab: differential use in psoriasis.乌司奴单抗：在银屑病中的差异化应用。
Clin Cosmet Investig Dermatol. 2011;4:93-9. doi: 10.2147/CCID.S17917. Epub 2011 Jul 1.
Zotero 插件